Illuminating Heavy Metals Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Illuminating Heavy Metals Testing
USP <231> Heavy Metals is transitioning toward the incorporation of modern quantitative technologies, but there is still much to be resolved.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 36-42

The stimuli article


Figure 1: Decision tree for analytical method selection (1). (FIGURES IS ADAPTED FROM USP.)
The stimuli article (found at http://www.usp.org/pdf/EN/USPNF/2008-04-10InorganicImpuritiesStim.pdf) proposes replacing USP ‹231› with an instrument-based screening method that is more accurate and practical. It proposes expanding the application of USP ‹231› to 31 elements (see sidebar, "Elements under consideration for USP ‹231› revision"), provides a decision tree for determining the means of sample preparation (see Figure 1), lists oral and parenteral limits for each element, and states USP will provide performance-based reference standards depending on whether the test articles are soluble in aqueous solutions, organic solvents, or apply to closed-vessel microwave digestion. However, the stimuli article does not yet include the preparation technique for digesting solid samples, converting them to liquids so that they can be introduced into the instruments.

The stimuli article also states that to perform a multi-element analysis, an inductively coupled plasma (ICP) spectrometer, either in the atomic (optical) emission or mass spectrometry (MS) mode is "required" (1). ICP–MS is about 1000 times more sensitive (to parts per billion level) than ICP alone (to parts per million level). ICP–MS detects and provides concentration amounts for nearly 60 elements at one time, while ICP alone can detect about 30 elements simultaneously. At the 2008 USP Annual Meeting, however, it was stated that the ICP methods are options for analytical determinations. Analysts are free to validate methods or procedures that work for their sample, including atomic absorption (AA) spectroscopy, which is element specific and as sensitive as optical ICP (2).

Industry concerns

The comment period for the stimuli article ended Dec. 15, 2008. USP plans to issue a draft document by July or August 2009, with the final General Chapter taking effect mid-2010. Most of industry's concerns focused on the following (opinions expressed in this article are those of the individuals and may not represent those of their company or affiliation).


Elements under consideration for USP ‹231› revision
Too many elements. Of the known elements listed in the stimuli article (see sidebar, "Elements under consideration for USP ‹231› revision"), four heavy metals are known to be the greatest toxic threat to humans and to the environment: lead, mercury, cadmium, and arsenic (i.e., "the big four"). Several groups have suggested that USP focus on these four first.

"It seems that they are trying to bite off more than they can chew all at once," says David Schoneker, past chairman of IPEC-Americas and member of Pharmaceutical Technology's Editorial Advisory Board. "Many of these individual metals have not undergone any routine testing in the past. You could have a real mess on your hands if suddenly this becomes official and pharmaceutical companies start sending out surveys to suppliers asking whether they meet all of the criteria for all of the metals. In many cases you're going to have supplier companies that will not waste resources to run tests for many of the metals because they feel that there is no chance of it being there based on their understanding of their raw materials and their manufacturing process. However, they may not have any actual test data to back that up and if this is not implemented carefully and for a smaller focused set of metals initially, there may be a lot of confusion about what information is appropriate and necessary to justify the supplier's statements."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here